Trends in psychotropic medication use among U.S. adults.

Pharmacoepidemiol Drug Saf

Division of Health and Nutrition Examination Surveys, National Center for Health Statistics, Centers for Disease Control and Prevention, Hyattsville, Maryland 20782, USA.

Published: May 2007

Purpose: To examine trends and prevalence of prescription psychotropic medication use among noninstitutionalized US adults.

Methods: Prescription medication data from the third National Health and Nutrition Examination Survey (NHANES; 1988-1994; n = 20 050) and the 1999-2002 NHANES (n = 12 060), two nationally representative cross-sectional health examination surveys, were examined for persons aged > or =17 years.

Results: The age-adjusted prevalence of psychotropic medication use increased from 6.1% in 1988-1994 to 11.1% in 1999-2002 (p < 0.001). This was due to more than a three-fold increase in antidepressant use (2.5%, 1988-1994 vs. 8.1%, 1999-2002 (p < 0.001)). Significant increases between time periods for antidepressant use were seen for all age, gender, and race-ethnic groups although increases were less pronounced for males than females and non-Hispanic blacks and Mexican Americans than non-Hispanic whites. Prevalence of use remained relatively constant from 1988-1994 to 1999-2002 for anxiolytic/sedative/hypnotic (ASH) medications (3.5-3.8%), antipsychotics (0.8-1.0%), and antimanic agents (0.3-0.4%). The age-adjusted prevalence of multiple psychotropic medication use increased from 1.2% in 1988-1994 to 3.1% in 1999-2002 (p < 0.001).

Conclusions: Psychotropic medication use among US adults increased since 1988-1994, specifically of antidepressants. Increases varied by gender and race-ethnicity indicating under-utilization for non-Hispanic blacks and Mexican Americans compared to non-Hispanic whites for both males and females.

Download full-text PDF

Source
http://dx.doi.org/10.1002/pds.1367DOI Listing

Publication Analysis

Top Keywords

psychotropic medication
20
medication adults
8
age-adjusted prevalence
8
medication increased
8
1999-2002 0001
8
males females
8
non-hispanic blacks
8
blacks mexican
8
mexican americans
8
non-hispanic whites
8

Similar Publications

Background: Posttraumatic stress disorder (PTSD) affects 3.9% of the general population. While massed cognitive processing therapy (CPT) has demonstrated efficacy in treating chronic PTSD, a substantial proportion of patients still continue to meet PTSD criteria after treatment, highlighting the need for novel therapeutic approaches.

View Article and Find Full Text PDF

Objective: To compare the prevalence of neurodevelopmental and mental health diagnoses in a national sample of youth with sex chromosome trisomies (SCTs) with matched controls.

Methods: Patients in PEDSnet and a diagnosis code mapping to 47,XXY/Klinefelter syndrome (n = 1171), 47,XYY/Double Y syndrome (n = 243), or 47,XXX/Trisomy X syndrome (n = 262) were matched with controls using propensity scores. Generalized estimating equations computed odds ratios (OR) with 95% confidence intervals (CI) for the prevalence of diagnoses within the neurodevelopmental and mental health composites, psychotropic medication prescriptions, and encounters with behavioral health and therapy providers.

View Article and Find Full Text PDF

Importance: A wide range of medications, noncombustible nicotine products, behavioral support, and alternative treatments are available in England to help people stop smoking. Understanding their effectiveness outside of clinical trial settings can support informed decision-making.

Objectives: To provide up-to-date estimates of the prevalence of different smoking cessation aids and associations with quit success and to explore moderation by socioeconomic position.

View Article and Find Full Text PDF

Purpose Of Review: Exploration of the potential of serotonergic psychedelic drugs, such as psilocybin and LSD, as potential treatments for headache disorders. This review addresses the need for well-informed physician guidelines and discusses mechanisms, safety, and efficacy of these treatments. Further research, including the consideration of combination with psychotherapy, is needed.

View Article and Find Full Text PDF

Objective: Bipolar disorder (BD), schizoaffective disorder (SAD), and schizophrenia (SCH) are psychiatric disorders characterized by persistent cognitive impairments, even during periods of remission. Psychotropic medications commonly used to manage these conditions have anticholinergic properties, which may contribute to cognitive impairment.

Methods: This study examined the relationship between anticholinergic medication burden and cognitive function in individuals diagnosed with BD, SAD, and SCH.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!